Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone (2023)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1016/s2214-109x(23)00410-2
PubMed Identifier: 37858585
Publication URI: http://europepmc.org/abstract/MED/37858585
Type: Journal Article/Review
Parent Publication: The Lancet Global Health
Issue: 11
ISSN: 2214-109X